Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 14, 2025
SBC Medical Group Holdings, Inc. Purchases 5 BTC
GlobeNewswire
·
April 14, 2025
IRVINE,Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings (Headquarters: California, USA; CEO: Yoshiyuki Aikawa) hereby announces that, based on the announcement of a decision to purchase Bitcoin (BTC) disclosed on February 12, 2025, it …
Relmada Therapeutics To Present NDV-01 Data at AUA2025
GlobeNewswire
·
April 14, 2025
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025 …
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
GlobeNewswire
·
April 14, 2025
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights …
Avicanna Reports Full Year 2024 Audited Financial Statement
GlobeNewswire
·
April 14, 2025
2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: …
SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
GlobeNewswire
·
April 14, 2025
DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that …
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
GlobeNewswire
·
April 14, 2025
Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and …
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
GlobeNewswire
·
April 14, 2025
LEIDEN, Netherlands …
Soleno Therapeutics Announces VYKAT(TM) XR Launch
GlobeNewswire
·
April 14, 2025
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of …
10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer
GlobeNewswire
·
April 14, 2025
BEND, Ore., April 14, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., craft beer brand (NASDAQ: TLRY and TSX: TLRY), introduces Camp Coldie, 10 Barrel Brewing Co.’s highly-crushable new 5% IPA brewed in partnership with Scout Campers. …
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
GlobeNewswire
·
April 14, 2025
FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter …
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire
·
April 14, 2025
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious …
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
GlobeNewswire
·
April 14, 2025
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its …
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
GlobeNewswire
·
April 14, 2025
25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, Gilles Gagnon to remain as a Strategic Advisor and …
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
GlobeNewswire
·
April 14, 2025
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million …
CORRECTION - New Guideline Aims to Transform Obesity Care for Children and Adolescents
GlobeNewswire
·
April 14, 2025
EDMONTON, Alberta, April 14, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, April 14th by Obesity Canada, please note that the title and link of the clinical practice guideline have been updated. The corrected release …
Press release: CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases
GlobeNewswire
·
April 14, 2025
CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2026 Rule, expected to be finalized in August 2025 and in effect by October …
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
GlobeNewswire
·
April 14, 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade …
New Guideline Aims to Transform Obesity Care for Children and Adolescents
GlobeNewswire
·
April 14, 2025
EDMONTON, Alberta, April 14, 2025 (GLOBE NEWSWIRE) -- Healthcare providers and families have a new roadmap to support collaborative, fully-informed, evidence-based care for children and adolescents living with obesity, thanks to a new clinical practice …